Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Clostridium Difficile Infection

In brief

This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.

Key facts

Study ID

NCT03200093

Run by

Rochester General Hospital

People needed

65

Starts

2017-06-08

Expected to finish

2021-04-22

Last updated by the study team

2021-04-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years and older
• Any history of Clostridium difficile infection based on a positive Clostridium difficile stool test performed at a lab affiliated with Rochester Regional Health System or patient report
• A new in-patient admission, with an antibiotic treatment plan for greater than 48 hours

You may not qualify if…

• Documented allergy and/or adverse drug reaction to vancomycin
• Pregnant
• Patients who are admitted with a current episode of Clostridium difficile infection
• Patients with total colectomy

Where it is running

• Rochester General Hospital — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.